Avicanna Reports Q2 2023 Financial Statement
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
TORONTO, Aug. 15, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company “) (TSX: AVCN)…
Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference…
The Leading AI-Powered Automation and Integration Platform Scored High in Criteria including Capabilities to Ease…
Advancement delivers sports broadcast impression data with better accuracy to benefit rights holders, teams, brands,…
High-growth business with audiovisual and digital divisions that produce dynamic content to engage, reward and…
MoneyLion donates to Boys & Girls Club of America while financially empowering teachers, parents and…
– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an…
– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an…
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper…
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…
Ninth patient dosed in ongoing Phase 1b trial evaluating tegoprubart in patients undergoing kidney transplantation;…
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program…
Camsirubicin Phase 1b Trial Currently at 5th Dose-Level (650 mg/m2), Generating Encouraging ResultsMNPR-101 Radiopharma Program…
88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the…
88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the…
Company receives further regulatory clarity from FDA on Phase 3 ENABLAR-2 study. Potential for enobosarm…